New Delhi: Glenmark Pharmaceuticals today said it has received US health regulator`s approval to market generic version of Forest Laboratories` Campral Delayed Release Tablets, a drug used for alcohol abstinence, in the American market. Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Ltd (GGL), has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Acamprosate Calcium Delayed Release Tablets, Glenmark Pharma said in a statement. GGL is a subsidiary of Mumbai-based Glenmark Pharmaceuticals Ltd. Based on IMS Health sales data for the 12 month period ending March 2013, Acamprosate, which is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence, garnered sales of USD 21 million.
High voter turnout in 5th phase of Lok Sabha polls
FIR against Misa for disturbing poll process
RCB play hard and party hard too: Mallya
Ananth Kumar calls Congress a non-performer across India